#151097

Anti-EGFR [F4]

Cat. #151097

Anti-EGFR [F4]

Cat. #: 151097

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Epidermal Growth Factor Receptor (EGFR, Her1)

Class: Monoclonal

Application: ELISA ; FACS ; IHC ; IP ; RIA

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Joyce Taylor-Papadimitriou

Institute: Cancer Research UK, London Research Institute: Lincoln's Inn Fields

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)

  • Name: Anti-EGFR [F4]
  • Research fields: Cancer;Cell signaling and signal transduction
  • Clone: F4
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: ELISA ; FACS ; IHC ; IP ; RIA
  • Description: The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). Dysregulation of EGFR signaling as a consequence of overexpression, amplification and mutation of the EGFR gene occurs frequently in several types of cancers and many become dependent on EGFR signaling to maintain their malignant phenotypes.
  • Immunogen: Synthetic peptide (residues 985 to 996 of human EGFR) coupled to keyhole limpet hemocyanin.
  • Isotype: IgG1 kappa
  • Myeloma used: P3/NS1/1-Ag4.1

Target Details

  • Target: Epidermal Growth Factor Receptor (EGFR, Her1)
  • Target background: The EGFR family of type I growth factor receptor tyrosine kinases includes EGFR (HER1), c-erbB2 (HER2; neu), c-erbB3 (HER3) and c-erbB4 (HER4). Dysregulation of EGFR signaling as a consequence of overexpression, amplification and mutation of the EGFR gene occurs frequently in several types of cancers and many become dependent on EGFR signaling to maintain their malignant phenotypes.

Applications

  • Application: ELISA ; FACS ; IHC ; IP ; RIA

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: '-15° C to -25° C
  • Shipping conditions: Dry ice

References

  • Gibson et al. 2009. PLoS One. 4(9):e7222. PMID: 19787046.
  • Berger et al. 1987. J Pathol. 152(4):297-307. PMID: 3668732.
  • Gullick et al. 1986. Cancer Res. 46(1):285-92. PMID: 2998607.

Tool enquiry

Please ensure you use your organisation email address rather than personal where possible, as this helps us locate your organisation in our system faster.

Please note we may take up to three days to respond to your enquiry.

CancerTools.org uses the contact information provided to respond to you about our research tools and service. For more information please review our privacy policy.